Key result
High neutrophil-to-lymphocyte ratio (>5) was independently associated with an increased risk of net clinical outcomes compared to low ratio (<3) in AF patients (aHR 1.99; 95% CI 1.37-2.87).
Why the study?
Systemic inflammation plays a central role in AF, and the authors hypothesized that the neutrophil-to-lymphocyte ratio is associated with an increased risk of adverse events in AF patients.
Does a high neutrophil-to-lymphocyte ratio predict adverse clinical outcomes in patients with atrial fibrillation receiving vitamin K antagonists?
Cohort (n=1,050)
Does a high neutrophil-to-lymphocyte ratio predict adverse clinical outcomes in patients with atrial fibrillation receiving vitamin K antagonists?
Hazard Ratio: 1.99 (95% CI 1.37–2.87)
p-value: p=<0.001
Elevated neutrophil-to-lymphocyte ratio is an independent prognostic biomarker for cardiovascular death, all-cause mortality, and net clinical outcomes in patients with atrial fibrillation on vitamin K antagonists.
May refine risk assessment in AF on VKAs but should not yet change practice; leaves open incremental value over existing scores.
BACKGROUND: Systemic inflammation plays a central role in atrial fibrillation (AF). The neutrophil-to-lymphocyte ratio (NLR) is a simple hematological index that has been shown to be associated with prognosis in different pathologies. HYPOTHESIS: The NLR is associated with an increased risk of adverse events in patients with AF. METHODS: We included a prospective cohort of AF patients who started vitamin K antagonists (VKAs) therapy between July 2016 and June 2018. NLR was assessed at baseline and classified into three categories: low (< 3), moderate (3-5), and high (> 5). During a 2-year follow-up period, all cardiovascular deaths, all-cause deaths, and net clinical outcomes (NCO; either ischemic stroke/transient ischemic attack, major bleeding or all-cause death), were recorded. RESULTS: A total of 1050 patients were included (51.4% women; median age 77 years). NLR was available in 936 patients: 507 (54.2%) had low NLR (< 3), 239 (25.5%) had moderate NLR (3-5), and 190 (20.3%) had high NLR (> 5). The primary endpoint was significantly increased in the high NLR category (p = 0.002 for cardiovascular death; p < 0.001 for all-cause mortality, and p < 0.001 for NCO), with higher IRRs (all p < 0.001). Multivariate Cox regression analyses showed that high NLR was independently associated with an increased risk of cardiovascular death (aHR: 2.02; 95% CI: 1.04-3.92), all-cause mortality (aHR: 2.51; 95% CI: 1.58-3.97), and NCO (aHR: 1.99; 95% CI: 1.37-2.87), compared to low NLR. CONCLUSIONS: In this prospective AF cohort receiving VKAs, elevated NLR was significantly associated with an increased risk of adverse clinical outcomes. NLR has independent prognostic value beyond other classical risk factors.
No takes yet. Share an insight, caveat, or question.
Soler‐Espejo et al. (2025) conducted a cohort in Atrial fibrillation (n=1,050). High neutrophil-to-lymphocyte ratio (> 5) vs. Low neutrophil-to-lymphocyte ratio (< 3) was evaluated on Net clinical outcomes (ischemic stroke/transient ischemic attack, major bleeding or all-cause death) (aHR 1.99, 95% CI 1.37-2.87, p=<0.001). High neutrophil-to-lymphocyte ratio (>5) was independently associated with an increased risk of net clinical outcomes compared to low ratio (<3) in AF patients (aHR 1.99; 95% CI 1.37-2.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: